Search | Page 6 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma

    ... Purpose:  Lenalidomide has been shown to have single agent activity in indolent ... The purpose of this study is to see how well giving lenalidomide together with rituximab works in treating patients with previously ...

    Clinical Trial last updated 06/06/2016 - 10:17am.

  2. Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's Experience

    ... use or response to hypomethylating agents were observed. Lenalidomide therapy was seldom used in AYA, as none presented with del5q. ...

    Research Article last updated 09/19/2016 - 11:09am.

  3. Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure

    ... architectures specifically upon treatment with lenalidomide and other drugs. Despite initial clinical response to ...

    Research Article last updated 07/18/2016 - 11:18am.

  4. Clinical Utility of Lenalidomide in the Treatment of Myelodysplastic Syndromes

    ... Abstract:  Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes ... This article reviews lenalidomide in the setting of myelodysplastic syndromes (MDS). ...

    Research Review last updated 05/02/2016 - 9:12am.

  5. Recent developments in myelodysplastic syndromes

    ... approval of azacitidine , decitabine , and lenalidomide between 2004 and 2006 seemed to herald a new era in the ...

    Research Article last updated 04/29/2016 - 11:34am.

  6. Myelodysplastic syndromes: Contemporary review and how we treat

    ... (HMA) azacitidine and decitabine and lenalidomide for MDS with isolated del(5q). To date, allogeneic stem ...

    Research Article last updated 04/29/2016 - 1:05pm.

  7. Personalized medicine for MDS

    ... treatment for MDS.  The classic example is the use of lenalidomide for patients with a del (5q) abnormality.  -In recent ... and the average length of response is 2 years.  -Lenalidomide works best in patients with red blood cell transfusion ...

    Research Review last updated 05/02/2016 - 9:44am.

  8. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

    ... isolated del(5q). METHODS: Patients received lenalidomide 10 mg/day (days 1-21; n = 47) or 5 mg/day (days 1-28; ... cycles, or placebo (n = 45). From the placebo and lenalidomide 5 mg groups, 84% and 58% of patients, respectively, crossed over ...

    Research Article last updated 07/29/2014 - 12:12pm.

  9. Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.

    ... supportive care alone, cytotoxic therapy, lenalidomide , histone deacetylase inhibitors, and HSCT, favorable ...

    Research Article last updated 11/19/2015 - 8:32am.

  10. Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia

    ... Azacitidine Lenalidomide Phase:  Phase 2 ... is a restricted distribution program for receiving lenalidomide ) Females of childbearing potential (FCBP)† must have a ...

    Clinical Trial last updated 06/06/2016 - 1:30pm.